SOD1 and Parkinson disease: Alternatively, these data may justify the evaluation of therapies that decrease SOD1 protein production as effective treatments against wild-type disSOD1 pathology in Parkinson disease, such as the FDA-approved antisense oligonucleotide Tofersen [74].